Since early August, the world’s most valuable pharmaceutical stock, Eli Lilly and Company (NYSE: LLY), has put on a stellar performance. After tanking 14% on Aug. 7 due to poor clinical trial results, shares have gained a whopping 71% year-to-date.
Lilly’s weight loss and diabetes drugs, Zepbound and Mounjaro, are the most efficacious of their kind currently available to patients. These therapies have allowed Lilly to take the pharmaceutical world by storm, with the stock reaching unprecedented milestones. Not too long ago, Lilly became the first pharmaceutical company to hit a $1 trillion market cap.
